Augustine Asset Management Inc. Sells 68 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Augustine Asset Management Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 4,474 shares of the biopharmaceutical company’s stock after selling 68 shares during the period. Regeneron Pharmaceuticals comprises 0.8% of Augustine Asset Management Inc.’s investment portfolio, making the stock its 22nd largest position. Augustine Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,187,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $37,000. Private Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $665.46 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $73.13 billion, a PE ratio of 17.38, a P/E/G ratio of 2.38 and a beta of 0.08. The firm has a fifty day simple moving average of $714.37 and a 200 day simple moving average of $906.38. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bank of America reiterated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.